Adagio Therapeutics Inc. is riding high after the company said its experimental antibody is likely to be just as effective against the omicron variant of the coronavirus as it is against previous variants. The antibody, a drug called ADG20, affords protection for up to one year, according to the firm, and is also being tested as a treatment for those already infected.
Adagio (Nasdaq: ADGI) shares had spiked by more than 80% by 2 p.m. Monday, trading at about $46 and giving…